Infliximab and Rheumatoid Arthritis

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Infliximab and Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by swollen of the joints, pain, impaired muscle strength, physical function, and fatigue. The latter symptom is believed to impose severe physical limitation to the patients, thereby impacting their quality of life (QOL). Fatigue has been recognized as a multi-causal, multidimensional and complex concept in which psychological, biochemical, and physiological factors play a role. In RA, little is known regarding the time-course of the effects of biologic medication on fatigue and its relationship with functional capacity, muscular strength, and QOL, as well as disease activity and inflammatory parameters. Therefore, the purpose of this study was to evaluate the temporal responses to infliximab in fatigue and other selected parameters of physical function, inflammation, disease activity, and QOL in a cohort of RA patients. For more information regarding this article, kindly go through the above link.

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger